{
    "id": 2643,
    "name": "perivascular epithelioid cell tumor",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:2643",
    "evidence": [
        {
            "id": 17206,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, ABI-009 (Nab-Rapamycin) treatment of malignant perivascular epithelioid cell patients resulted in partial response in 20% (1/5) of patients with TSC1 mutations, 100% (9/9) of patients with TSC2 patients, and 9% (1/11) of patients without a TSC mutation (J Clin Oncol 37, 2019 (suppl; abstr 11005); NCT02494570).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 3380,
                "therapyName": "Nab-Rapamycin",
                "synonyms": null
            },
            "indication": {
                "id": 2643,
                "name": "perivascular epithelioid cell tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15230,
                    "pubMedId": null,
                    "title": "ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.",
                    "url": "https://abstracts.asco.org/239/AbstView_239_269473.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17207,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, ABI-009 (Nab-Rapamycin) treatment of malignant perivascular epithelioid cell patients resulted in partial response in 20% (1/5) of patients with TSC1 mutations, 100% (9/9) of patients with TSC2 patients, and 9% (1/11) of patients without a TSC mutation (J Clin Oncol 37, 2019 (suppl; abstr 11005); NCT02494570).",
            "molecularProfile": {
                "id": 1245,
                "profileName": "TSC2 mutant"
            },
            "therapy": {
                "id": 3380,
                "therapyName": "Nab-Rapamycin",
                "synonyms": null
            },
            "indication": {
                "id": 2643,
                "name": "perivascular epithelioid cell tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15230,
                    "pubMedId": null,
                    "title": "ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.",
                    "url": "https://abstracts.asco.org/239/AbstView_239_269473.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02494570",
            "title": "A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3380,
                    "therapyName": "Nab-Rapamycin",
                    "synonyms": null
                }
            ]
        }
    ]
}